HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

STAT+: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?

Exclusive: STAT has learned that Eli Lilly and the FDA allowed a 79-year-old to gain extraordinary access to an experimental obesity drug through the agency's "compassionate use" program.

By STAT News · Jun 23, 2026 · via STAT News
STAT+: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Amid efforts in Germany to retool the country's drug spending, the U.S. is launching an investigation into wha…
Jun 23, 2026
Exelixis' Cabometyx successor fails primary endpoint in colorectal cancer trial amid FDA review
The WeekFierceBiotech ↗
Exelixis' next franchise drug, zanzalintinib, has hit a clinical setback, although at least two groups of anal…
Jun 23, 2026
CARsgen Wins First-Ever Solid Tumor CAR-T Approval in China
The WeekBriefing
China grants CARsgen approval for a Claudin18.2-targeted therapy, marking the first CAR-T authorized for solid…
Jun 23, 2026